Cargando…
Clinical usefulness of the metabolic syndrome for the risk of coronary heart disease does not exceed the sum of its individual components in older men and women. The Three-City (3C) Study
OBJECTIVES: To investigate the respective associations and clinical usefulness of the metabolic syndrome (MetS) and its individual components to predict the risk of first coronary heart disease (CHD) events in elderly. DESIGN: The Three-City is a French prospective multisite community-based cohort....
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328398/ https://www.ncbi.nlm.nih.gov/pubmed/22505463 http://dx.doi.org/10.1136/heartjnl-2011-301185 |
_version_ | 1782229736339013632 |
---|---|
author | Rachas, Antoine Raffaitin, Christelle Barberger-Gateau, Pascale Helmer, Catherine Ritchie, Karen Tzourio, Christophe Amouyel, Philippe Ducimetière, Pierre Empana, Jean-Philippe |
author_facet | Rachas, Antoine Raffaitin, Christelle Barberger-Gateau, Pascale Helmer, Catherine Ritchie, Karen Tzourio, Christophe Amouyel, Philippe Ducimetière, Pierre Empana, Jean-Philippe |
author_sort | Rachas, Antoine |
collection | PubMed |
description | OBJECTIVES: To investigate the respective associations and clinical usefulness of the metabolic syndrome (MetS) and its individual components to predict the risk of first coronary heart disease (CHD) events in elderly. DESIGN: The Three-City is a French prospective multisite community-based cohort. SETTING: Three large French cities: Bordeaux, Dijon and Montpellier. PARTICIPANTS: 7612 subjects aged 65 and over who were free of CHD at baseline. MAIN OUTCOME MEASURES: The MetS was defined by the 2005 National Cholesterol Education Program Adult Treatment Panel III criteria. RESULTS: During a median follow-up of 5.2 years, 275 first CHD events were adjudicated. The MetS was associated with increased risks of total (adjusted HR: 1.78; 95% CI 1.39 to 2.28), fatal (HR: 2.40; 95% CI 1.41 to 4.09) and non-fatal (HR: 1.64; 95% CI 1.24 to 2.17) CHD events. The association with total CHD was significant in women (HR: 2.56; 95% CI 1.75 to 3.75) but not in men (HR: 1.39; 95% CI 0.99 to 1.94; p for interaction=0.012). When in the same multivariable model, hyperglycemia and abdominal adiposity in women, hyperglycemia, lower HDL cholesterol and abdominal adiposity (inverse association) in men were the components significantly associated with CHD. The components of the MetS but not the MetS itself improved risk prediction beyond traditional risk factors (NRI= 9.35%, p<0;001). CONCLUSION: The MetS is a risk marker for CHD in community-dwelling elderly subjects but may not be useful for CHD risk prediction purposes compared to its individual components. |
format | Online Article Text |
id | pubmed-3328398 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BMJ Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-33283982012-04-17 Clinical usefulness of the metabolic syndrome for the risk of coronary heart disease does not exceed the sum of its individual components in older men and women. The Three-City (3C) Study Rachas, Antoine Raffaitin, Christelle Barberger-Gateau, Pascale Helmer, Catherine Ritchie, Karen Tzourio, Christophe Amouyel, Philippe Ducimetière, Pierre Empana, Jean-Philippe Heart Epidemiology OBJECTIVES: To investigate the respective associations and clinical usefulness of the metabolic syndrome (MetS) and its individual components to predict the risk of first coronary heart disease (CHD) events in elderly. DESIGN: The Three-City is a French prospective multisite community-based cohort. SETTING: Three large French cities: Bordeaux, Dijon and Montpellier. PARTICIPANTS: 7612 subjects aged 65 and over who were free of CHD at baseline. MAIN OUTCOME MEASURES: The MetS was defined by the 2005 National Cholesterol Education Program Adult Treatment Panel III criteria. RESULTS: During a median follow-up of 5.2 years, 275 first CHD events were adjudicated. The MetS was associated with increased risks of total (adjusted HR: 1.78; 95% CI 1.39 to 2.28), fatal (HR: 2.40; 95% CI 1.41 to 4.09) and non-fatal (HR: 1.64; 95% CI 1.24 to 2.17) CHD events. The association with total CHD was significant in women (HR: 2.56; 95% CI 1.75 to 3.75) but not in men (HR: 1.39; 95% CI 0.99 to 1.94; p for interaction=0.012). When in the same multivariable model, hyperglycemia and abdominal adiposity in women, hyperglycemia, lower HDL cholesterol and abdominal adiposity (inverse association) in men were the components significantly associated with CHD. The components of the MetS but not the MetS itself improved risk prediction beyond traditional risk factors (NRI= 9.35%, p<0;001). CONCLUSION: The MetS is a risk marker for CHD in community-dwelling elderly subjects but may not be useful for CHD risk prediction purposes compared to its individual components. BMJ Group 2012-04-15 /pmc/articles/PMC3328398/ /pubmed/22505463 http://dx.doi.org/10.1136/heartjnl-2011-301185 Text en © 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode. |
spellingShingle | Epidemiology Rachas, Antoine Raffaitin, Christelle Barberger-Gateau, Pascale Helmer, Catherine Ritchie, Karen Tzourio, Christophe Amouyel, Philippe Ducimetière, Pierre Empana, Jean-Philippe Clinical usefulness of the metabolic syndrome for the risk of coronary heart disease does not exceed the sum of its individual components in older men and women. The Three-City (3C) Study |
title | Clinical usefulness of the metabolic syndrome for the risk of coronary heart disease does not exceed the sum of its individual components in older men and women. The Three-City (3C) Study |
title_full | Clinical usefulness of the metabolic syndrome for the risk of coronary heart disease does not exceed the sum of its individual components in older men and women. The Three-City (3C) Study |
title_fullStr | Clinical usefulness of the metabolic syndrome for the risk of coronary heart disease does not exceed the sum of its individual components in older men and women. The Three-City (3C) Study |
title_full_unstemmed | Clinical usefulness of the metabolic syndrome for the risk of coronary heart disease does not exceed the sum of its individual components in older men and women. The Three-City (3C) Study |
title_short | Clinical usefulness of the metabolic syndrome for the risk of coronary heart disease does not exceed the sum of its individual components in older men and women. The Three-City (3C) Study |
title_sort | clinical usefulness of the metabolic syndrome for the risk of coronary heart disease does not exceed the sum of its individual components in older men and women. the three-city (3c) study |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328398/ https://www.ncbi.nlm.nih.gov/pubmed/22505463 http://dx.doi.org/10.1136/heartjnl-2011-301185 |
work_keys_str_mv | AT rachasantoine clinicalusefulnessofthemetabolicsyndromefortheriskofcoronaryheartdiseasedoesnotexceedthesumofitsindividualcomponentsinoldermenandwomenthethreecity3cstudy AT raffaitinchristelle clinicalusefulnessofthemetabolicsyndromefortheriskofcoronaryheartdiseasedoesnotexceedthesumofitsindividualcomponentsinoldermenandwomenthethreecity3cstudy AT barbergergateaupascale clinicalusefulnessofthemetabolicsyndromefortheriskofcoronaryheartdiseasedoesnotexceedthesumofitsindividualcomponentsinoldermenandwomenthethreecity3cstudy AT helmercatherine clinicalusefulnessofthemetabolicsyndromefortheriskofcoronaryheartdiseasedoesnotexceedthesumofitsindividualcomponentsinoldermenandwomenthethreecity3cstudy AT ritchiekaren clinicalusefulnessofthemetabolicsyndromefortheriskofcoronaryheartdiseasedoesnotexceedthesumofitsindividualcomponentsinoldermenandwomenthethreecity3cstudy AT tzouriochristophe clinicalusefulnessofthemetabolicsyndromefortheriskofcoronaryheartdiseasedoesnotexceedthesumofitsindividualcomponentsinoldermenandwomenthethreecity3cstudy AT amouyelphilippe clinicalusefulnessofthemetabolicsyndromefortheriskofcoronaryheartdiseasedoesnotexceedthesumofitsindividualcomponentsinoldermenandwomenthethreecity3cstudy AT ducimetierepierre clinicalusefulnessofthemetabolicsyndromefortheriskofcoronaryheartdiseasedoesnotexceedthesumofitsindividualcomponentsinoldermenandwomenthethreecity3cstudy AT empanajeanphilippe clinicalusefulnessofthemetabolicsyndromefortheriskofcoronaryheartdiseasedoesnotexceedthesumofitsindividualcomponentsinoldermenandwomenthethreecity3cstudy |